inflammationimmune-supportmood

Low Dose Naltrexone (LDN)

Low Dose Naltrexone (LDN)

Calm inflammation and reset your immune system

Moderate Preclinical / Emerging HumanPrescription only; available via telehealth

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →

Quick Reference

Peptide ClassOpioid Antagonist / Immunomodulator
Half-Life4-6 hours (but immunomodulatory effects persist)
AdministrationOral
Typical Dosage1.5-4.5mg at bedtime
Cycle LengthOngoing; typically taken nightly
Evidence LevelModerate Preclinical / Emerging Human
Legal StatusPrescription only; available via telehealth
Approximate Cost$30-80/month via compounding pharmacy

How Low Dose Naltrexone (LDN) Works

Transiently blocks opioid receptors to upregulate endorphins and modulate TLR4 immune signaling

At low doses, naltrexone briefly blocks opioid receptors, causing a compensatory upregulation of endogenous opioids (endorphins and enkephalins). It also directly modulates toll-like receptor 4 (TLR4) signaling on immune cells, reducing pro-inflammatory cytokine production. This dual mechanism makes it uniquely effective for inflammatory and autoimmune conditions.

Evidence Base

Preclinical Evidence

Animal models show anti-inflammatory, neuroprotective, and anti-tumor effects.

Human Evidence

Clinical trials confirm efficacy in Crohn's disease, fibromyalgia, MS, and CRPS.

Anecdotal Evidence

Users with autoimmune conditions report significant inflammation reduction and mood improvement within weeks.

Key PubMed References:

Free Personalized Analysis

Is Low Dose Naltrexone (LDN) right for your biology?

Take the 5-minute PeptidePilot quiz to get a personalized peptide match based on your goals, body, and lifestyle. Independent and vendor-neutral.

Safety Profile

Side Effects

Vivid dreams during the first 2-4 weeks (most common). Mild nausea at initiation. Both typically resolve with continued use.

Contraindications

Current opioid use (LDN will precipitate withdrawal). Pregnancy. Do not use within 7-10 days of opioid discontinuation.

PeptidePilot Assessment

LDN is PeptidePilot's top recommendation for users with chronic inflammation, autoimmune conditions, or mood disorders as primary concerns. Its exceptional safety profile and low cost make it one of the highest-value interventions available through telehealth.

📊 8% of PeptidePilot users with inflammation and mood as co-primary concerns receive LDN as their top match

Frequently Asked Questions

Explore More Peptides